目的: 建立同时测定重症加强护理病房(ICU)中耐碳青霉烯肠杆菌(CRE)感染患者替加环素及阿米卡星的血浆药物浓度的液相色谱-串联质谱(LC-MS/MS)方法,并将其应用于治疗药物监测(TDM)中。方法: 血浆样品加入内标米诺环素及卡那霉素的甲醇溶液及氢氧化钠溶液,采用乙酸乙酯与二氯甲烷混合溶液提取,取上清液氮气吹干,加入甲醇复溶后进样分析。采用Waters Cortecs C18 (100 mm×4.6 mm,2.7 μm)色谱柱,流动相A为甲醇,流动相B为甲酸-甲酸铵水溶液,流速0.3 mL·min-1,进样量2 μL。检测以电喷雾离子源,正离子扫描,多反应监测模式进行。结果: 替加环素及阿米卡星在ICU患者血浆中的线性范围及定量限均符合测定要求,批内、批间精密度、提取回收率、基质效应及稳定性均<15%。收集到10例同时接受替加环素(50 mg,每12 h服用1次)和阿米卡星(0.8 g,每天服用1次)治疗的CRE感染重症患者样本,2种药物血浆中稳态谷浓度分别为(88.45±98.97)ng·mL-1及(2.98±1.59)μg·mL-1,存在较大个体差异。结论: 本方法快速、灵敏,专属性强且重复性好,可进行CRE感染的ICU患者临床TDM工作。
饶志, 郭思鸣, 何忠芳, 党子龙, 李波霞, 秦红岩, 魏玉辉
. LC-MS/MS法同时测定耐碳青霉烯肠杆菌感染重症患者血浆中替加环素及阿米卡星的药物浓度*[J]. 药物分析杂志, 2023
, 43(3)
: 387
-393
.
DOI: 10.16155/j.0254-1793.2023.03.04
Objective: To develop a method for simultaneous determination of the plasma drug concentrations of tegacyclin and amikacin in infection in intensive care unit (ICU) patients with carbapenem resistant enterobacteriaceae (CRE) using LC-MS/MS, and apply it to the therapeutic drug monitoring (TDM). Methods: NaOH solution and methanol solution with internal standards of minocycline and kanamycin were added into plasma samples. The resulting solution was then extracted with the mixed solution of ethyl acetate and methylene chloride. The supernatant was dried with nitrogen and re-dissolved in methanol. Determination was carried out with a waters Cortec C18 (100 mm×4.6 mm, 2.7 μm) chromatographic column. Mobile phase A was methanol, mobile phase B was formic acid / ammonium formate aqueous solution, the flow rate was 0.3 mL·min-1, and the injection volume was 2 μL. Electrospray spray ion source, positive ion scanning and multiple reaction monitoring mode were used. Results: The linear range and quantitative limit of tegacyclin and amikacin both met the requirements. The inter-and intra-day precision and matrix effect were all <15%. Samples of ten patients treated with tegacyclin (50 mg, q12h) and amikacin (0.8 g, qd) were collected. The steady-state trough concentrations of tegacyclin and amikacin in ten ICU patients with CRE infection were (83.86±84.56) ng·mL-1 and (83.86±84.56) ng·mL-1, respectively. There were large individual differences caused by the two antibiotics. Conclusion: This method is rapid, sensitive, specific and reproducible. It can be used for clinical TDM of ICU patients with CRE infection.
[1] MIHRET T, KASSA Y, GEDEFIE A, et al. Emerging carbapenem-resistant enterobacteriaceae infection, its epidemiology and novel treatment options: a review [J].Infect Drug Resist, 2021, 14: 4363
[2] LIN Q, WANG Y, YU J, et al. Bacterial characteristics of carbapenem-resistant enterobacteria-ceae (CRE) colonized strains and their correlation with subsequent infection [J].BMC Infect Dis, 2021, 21: 638
[3] SHEU CC, CHANG YT, LIN SY, et al. Infections caused by carbapenem-resistan enterobacte-riaceae: an update on therapeutic options [J].Front Microbiol, 2019, 10: 80
[4] MIHRET T, YESHIMEBET K, ALEMU G, et al. Emerging Carbapenem-resistant enterobacte riaceae infection, its epidemiology and novel treatment options: a review [J].Infect Drug Resist, 2021, 14: 4363
[5] FEDERICO P, NADIM G, CHAKHTOURA EI, et al. Treatment options for infections caused by carbapenem-resistant enterobacteriaceae: Can we apply “precision medicine” to antimicrobial chemotherapy [J].Expert Opin Pharmacother, 2016, 17(6):761
[6] ELIZABETH AN, JASON CG. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically ill patients infected with carbapenem-resistant enterobacteriaceae [J].Virulence, 2017, 8(4):440
[7] SUAY-GARCIA B, PEREZ-GRACIA MT. Present and future of carbapenem-resistant enterobacteriaceae (CRE) infections [J].Antibiotics (Basel), 2019, 8(3):122
[8] KHILNANI GC, ZIRPE K, HADDA V, et al. Guidelines for antibiotic prescription in intensive care unit [J].Indian J Crit Care Med, 2019, 23(Suppl 1):S1
[9] CLOESMEIJER ME, VAN DEN OEVER HLA, MATHOT RAA, et al. Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics [J].Br J Clin Pharmacol, 2020, 86(8):1620
[10] SCHOUTEN J, WAELE JD, LANCKOHR C, et al. Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns [J].Int J Antimicrob Agents, 2021, 58(4):106409
[11] 国卫办医发[2020]8号. 关于持续做好抗菌药物临床应用管理工作的通知 [Z]. 2020
Notice on the Continuous Improvement of Management about Clinical Application of Antibacterlal Drugs[Z]. 2020
[12] MONIZ P, COELHO L, POVOA P. Antimicrobial stewardship in the intensive care unit: the role of biomarkers, pharmacokinetics, and pharmacodynamics [J].Adv Ther, 2021, 38(1):164
[13] WELTE R, OBERACHER H, GASPERETTI T, et al. Pharmacokinetics and antifungal activity of echinocandins in ascites fluid of critically ill patients [J].Antimicrob Agents Chemother, 2021, 65(7):e02565
[14] MARTY FM, CHOY YM, VER DER HORST C, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase Ⅱ study [J].J Infect Dis, 2014, 209(4):542
[15] CHAN K, WANG W, LEDESMA KR, et al. A robust LC-MS/MS method for amikacin: application to cellular uptake and pharmacokinetic studies [J].Bioanalysis, 2020, 12(7):445
[16] CHAN K, LEDESMA CK, WANG W, et al. Characterization of amikacin drug exposure and nephrotoxicity in an animal model [J].Antimicrob Agents Chemother, 2020, 64(9):e00859
[17] NIETO JE, TRELA J, STANLEY SD, et al. Pharmacokinetics of a combination of amikacin sulfate and penicillin G sodium for intravenous regional limb perfusion in adult horses [J].Can J Vet Res, 2016, 80(3):230
[18] YAO F, WANG Y, HOU Y, et al. Establishment and validation of a liquid chromatography-tandem mass spectrometry method for the determination of tigecycline in critically ill patients [J].Int J Anal Chem, 2020, 12: 6671392
[19] YANG T, MEI H, WANG J, et al. Therapeutic drug monitoring of tigecycline in 67 infected patients and a population pharmacokinetics/microbiological evaluation of A. baumannii study [J].Front Microbiol, 2021, 12: 678165
